Payers across Europe have experimented with the implementation of benefit-sharing programs to support the rational prescribing of biologics. This study addresses knowledge gaps concerning benefit-sharing strategies and provides recommendations for their optimal design and implementation. 
This study is based on a literature review and on semi-structured interviews with payers/insurers, policy-makers, healthcare professionals and industry representatives in England, France, Germany, Ireland, Italy, the Netherlands, Poland, Portugal, Romania and Scotland.
Our analysis revealed very variable design characteristics for benefit-sharing programs, depending on the organisation of the healthcare system, the specific time frame, the care setting and the policy environment. We also noted a generalised lack of transparency regarding the distribution of savings and how they are reinvested. This has raised questions on how to properly engage all stakeholders and on how to optimally implement benefit-sharing in the future.
To realise the full potential of benefit-sharing programs we identify the importance of 1) setting-up and timely monitoring success indicators for these programs; 2) including quality of care parameters as success indicators; 3) establishing clear pathways for the transparent distribution of savings; 4) transparently communicating with patients about the outcomes of benefit-sharing programs.

Benefit-Sharing Programs for Biologics: A European Comparative Analysis of Implementation Challenges

DIA Europe 2022

A global, member-driven non-profit organization mobilizing life sciences and healthcare. DIA fosters innovation to improve health and well-being worldwide. Professionals from 80 countries continue to engage with DIA through our unparalleled membership network, educational offerings, and professional development opportunities.